Russell Investments Group Ltd. Sells 9,725 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Russell Investments Group Ltd. lessened its position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) by 36.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,928 shares of the company’s stock after selling 9,725 shares during the period. Russell Investments Group Ltd.’s holdings in Y-mAbs Therapeutics were worth $115,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. China Universal Asset Management Co. Ltd. acquired a new stake in Y-mAbs Therapeutics in the 4th quarter valued at approximately $34,000. Bailard Inc. bought a new stake in shares of Y-mAbs Therapeutics in the fourth quarter worth $115,000. SG Americas Securities LLC boosted its holdings in Y-mAbs Therapeutics by 17.5% during the fourth quarter. SG Americas Securities LLC now owns 21,559 shares of the company’s stock worth $147,000 after purchasing an additional 3,210 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Y-mAbs Therapeutics by 4.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 26,090 shares of the company’s stock valued at $178,000 after purchasing an additional 1,089 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its position in Y-mAbs Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 28,095 shares of the company’s stock valued at $192,000 after purchasing an additional 7,124 shares in the last quarter. Institutional investors and hedge funds own 70.85% of the company’s stock.

Y-mAbs Therapeutics Trading Down 3.5 %

YMAB stock opened at $12.40 on Friday. The business’s 50 day simple moving average is $14.66 and its 200 day simple moving average is $11.63. Y-mAbs Therapeutics, Inc. has a 1-year low of $4.60 and a 1-year high of $20.90. The firm has a market capitalization of $544.11 million, a PE ratio of -25.31 and a beta of 0.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Thursday, February 29th. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.17. The firm had revenue of $23.36 million for the quarter, compared to the consensus estimate of $21.72 million. Y-mAbs Therapeutics had a negative net margin of 25.64% and a negative return on equity of 21.40%. As a group, sell-side analysts predict that Y-mAbs Therapeutics, Inc. will post -0.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, SVP Vignesh Rajah sold 1,711 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $16.53, for a total transaction of $28,282.83. Following the completion of the sale, the senior vice president now owns 33,889 shares in the company, valued at $560,185.17. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, SVP Vignesh Rajah sold 1,711 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total value of $28,282.83. Following the completion of the sale, the senior vice president now owns 33,889 shares of the company’s stock, valued at $560,185.17. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Thomas Gad sold 25,000 shares of the company’s stock in a transaction dated Tuesday, May 21st. The shares were sold at an average price of $12.00, for a total transaction of $300,000.00. Following the completion of the transaction, the insider now owns 240,032 shares in the company, valued at $2,880,384. The disclosure for this sale can be found here. Insiders sold 34,062 shares of company stock worth $423,846 over the last three months. Insiders own 21.50% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently weighed in on YMAB. HC Wainwright raised their price objective on Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, May 13th. Wedbush reiterated an “outperform” rating and set a $18.00 price objective (up previously from $12.00) on shares of Y-mAbs Therapeutics in a research note on Monday, February 12th. Canaccord Genuity Group raised their target price on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Monday, March 4th. Finally, BMO Capital Markets upped their price target on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an “outperform” rating in a research report on Monday, March 4th. Two investment analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $17.33.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.